CORRECTION article

Front. Microbiol., 05 November 2019

Sec. Antimicrobials, Resistance and Chemotherapy

Volume 10 - 2019 | https://doi.org/10.3389/fmicb.2019.02517

Corrigendum: A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis

  • 1. School of Pharmaceutical Sciences, Universidade Estadual Paulista, Araraquara, Brazil

  • 2. Department of Chemistry, Universidade Federal de São Carlos, São Carlos, Brazil

  • 3. Environmental Studies Center, Universidade Estadual Paulista, Rio Claro, Brazil

  • 4. Department of Clinical Analysis and Biomedicine, State University of Maringa, Maringá, Brazil

In the original article, we neglected to include the funder Grant # 2018/00163-0 São Paulo Research Foundation (FAPESP), to for all authors.

The FUNDING is: “This research was funded by grant #2013/14957-5, grant #2013/09265-7 and grant #2018/00163-0 São Paulo Research Foundation (FAPESP) by the Coordination for the Improvement of Higher Education Personnel (CAPES) together with the Post-Doctoral National Program (PNPD), the Programa de Apoio ao Desenvolvimento Científico (PADC) of School of Pharmaceutical Sciences/UNESP, Brazil and the authors thank UNESP for the data of the dissertation (Freitas, 2015).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

References

  • 1

    FreitasE. S. (2015). Nanoencapsulação De Compostos De Rutênio, Análise De Sua Atividade Anti-Mycobacterium Tuberculosis E Biodisponibilidade Oral. Ph.D. thesis, São Paulo State University, São Paulo.

Summary

Keywords

ruthenium(II) complexes, tuberculosis, nanotechnology, oral bioavailability, ICP-MS

Citation

da Silva PB, de Freitas ES, Solcia MC, de Souza PC, da Silva MM, Batista AA, Eismann CE, Rolisola AMCM, Menegário AA, Cardoso RF, Chorilli M and Pavan FR (2019) Corrigendum: A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis. Front. Microbiol. 10:2517. doi: 10.3389/fmicb.2019.02517

Received

17 October 2019

Accepted

18 October 2019

Published

05 November 2019

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

10 - 2019

Updates

Copyright

*Correspondence: Patricia B. da Silva Fernando R. Pavan ;

This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics